Literature DB >> 3137241

Modulation of serum follicle-stimulating hormone bioactivity and isoform distribution by estrogenic steroids in normal women and in gonadal dysgenesis.

V Padmanabhan1, L L Lang, J Sonstein, R P Kelch, I Z Beitins.   

Abstract

To determine the influence of estrogenic steroids on serum FSH bioactivity (B) and immunoreactivity (I) and the FSH isoform distribution profiles, we studied normal women during ovulatory menstrual cycles and a patient with gonadal dysgenesis treated with diethylstilbestrol (DES). Four women with ovulatory menstrual cycles, as judged from their serum immunoreactive LH, FSH, progesterone, and estradiol profiles in daily blood samples, had a significant increase in the mean FSH B/I ratio (P less than 0.05) during the midcycle phase of their menstrual cycles. Similarly, in the patient with gonadal dysgenesis the FSH B/I ratio rose significantly (P less than 0.05) after 3 weeks of DES treatment and declined during the posttreatment period. In five additional normal women, serum obtained during the follicular, midcycle, and luteal phases of their menstrual cycles was chromatofocused, and the FSH isoform distribution pattern determined. Sera obtained from the patient with gonadal dysgenesis before, during, and after DES administration were pooled and studied similarly. Chromatofocusing of a human pituitary tumor extract allowed for determination of the FSH B/I ratio in different pH ranges. The highest FSH B/I ratio was found in the more basic fractions (pH range 5.6-6.0) compared to the acidic fractions. During both the midcycle phase of the normal cycles and the DES administration period in the studies of the patient with gonadal dysgenesis, there was a shift of the FSH isoforms (as measured by immunoassay) to the basic pH range. In contrast, the mid- to late luteal phase samples, which had low B/I ratios, had an increase in FSH isoforms in the acidic pH range (less than 4.8). Similarly, in the patient with gonadal dysgenesis FSH isoforms in the basic range were more abundant during the DES treatment period than in the pre- or posttreatment serum pools. Therefore, it appears that endogenous and exogenous estrogenic stimulation alters FSH isoform distribution such that FSH isoforms that are more basic and have increased biological activity are secreted.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137241     DOI: 10.1210/jcem-67-3-465

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Efficacy of a combined protocol of urinary and recombinant follicle-stimulating hormone used for ovarian stimulation of patients undergoing ICSI cycle.

Authors:  Arianna Pacchiarotti; Cesare Aragona; Renzo Gaglione; Helmy Selman
Journal:  J Assist Reprod Genet       Date:  2007-07-26       Impact factor: 3.412

Review 2.  In vitro bioassays of follicle-stimulating hormone: methods and clinical applications.

Authors:  M Simoni; E Nieschlag
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

3.  Developmental programming: exogenous gonadotropin treatment rescues ovulatory function but does not completely normalize ovarian function in sheep treated prenatally with testosterone.

Authors:  Teresa L Steckler; James S Lee; Wen Ye; E Keith Inskeep; Vasantha Padmanabhan
Journal:  Biol Reprod       Date:  2008-06-04       Impact factor: 4.285

4.  A human FSHB transgene encoding the double N-glycosylation mutant (Asn(7Δ) Asn(24Δ)) FSHβ subunit fails to rescue Fshb null mice.

Authors:  Huizhen Wang; Vladimir Butnev; George R Bousfield; T Rajendra Kumar
Journal:  Mol Cell Endocrinol       Date:  2016-02-19       Impact factor: 4.102

5.  Receptor binding activity and in vitro biological activity of the human FSH charge isoforms as disclosed by heterologous and homologous assay systems: implications for the structure-function relationship of the FSH variants.

Authors:  E Zambrano; T Zariñán; A Olivares; J Barrios-de-Tomasi; A Ulloa-Aguirre
Journal:  Endocrine       Date:  1999-04       Impact factor: 3.633

Review 6.  Are circulating gonadotropin isoforms naturally occurring biased agonists? Basic and therapeutic implications.

Authors:  Brian J Arey; Francisco J López
Journal:  Rev Endocr Metab Disord       Date:  2011-12       Impact factor: 6.514

7.  Effects of 17beta-oestradiol and norethisterone acetate on sulfonation and sialylation of gonadotrophins in post-menopausal women.

Authors:  Leif Wide; Tord Naessén; Karin Eriksson
Journal:  Ups J Med Sci       Date:  2010-05       Impact factor: 2.384

8.  Normogonadotropic primary amenorrhea in a growth hormone-deficient woman with ectopic posterior pituitary: gonadotropin pulsatility and follicle-stimulating hormone bioactivity.

Authors:  B Crottaz; A Uské; M J Reymond; F Rey; E Temler; M Germond; F Gomez
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

9.  Serum FSH bioactivity and inhibin levels in patients with gonadotropin secreting and nonfunctioning pituitary adenomas.

Authors:  S Borgato; L Persani; R Romoli; D Cortelazzi; A Spada; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

10.  Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review.

Authors:  Bernd Th Krause; Ralf Ohlinger; Annette Haase
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.